MARKET

CTXR

CTXR

Citius Pharmaceuticals Inc
NASDAQ
0.8993
+0.0878
+10.82%
After Hours: 0.8842 -0.0151 -1.68% 19:46 02/11 EST
OPEN
0.8300
PREV CLOSE
0.8115
HIGH
0.9000
LOW
0.7902
VOLUME
1.46M
TURNOVER
--
52 WEEK HIGH
2.970
52 WEEK LOW
0.6300
MARKET CAP
20.12M
P/E (TTM)
-0.2658
1D
5D
1M
3M
1Y
5Y
1D
Citius Oncology Signs Exclusive Distribution Agreement With Uniphar for LYMPHIR in Europe
Reuters · 15h ago
CITIUS ONCOLOGY EXPANDS INTERNATIONAL DISTRIBUTION OF LYMPHIR™ TO EUROPEAN UNION THROUGH EXCLUSIVE AGREEMENT WITH UNIPHAR
Reuters · 15h ago
Weekly Report: what happened at CTXR last week (0202-0206)?
Weekly Report · 2d ago
Weekly Report: what happened at CTXR last week (0126-0130)?
Weekly Report · 02/02 09:48
Citius Oncology Inc. Files Information Statement Detailing Authorized Corporate Actions
Reuters · 01/29 21:31
Weekly Report: what happened at CTXR last week (0119-0123)?
Weekly Report · 01/26 09:49
Citius Oncology Inc. Files Draft Information Statement Outlining Authorized Corporate Actions
Reuters · 01/20 21:31
Weekly Report: what happened at CTXR last week (0112-0116)?
Weekly Report · 01/19 09:52
More
About CTXR
Citius Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of first-in-class critical care products, with a pipeline of anti-infectives in oncology, adjunct cancer care, stem cell therapy and prescription products. The Company's FDA approved LYMPHIR candidate is a targeted immunotherapy for an initial indication in the treatment of cutaneous T-cell lymphoma. Its late-stage pipeline also includes Mino-Lok, and CITI-002 (Halo-Lido). Mino-Lok is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections (CRBSIs) and central line associated bloodstream infections (CLABSIs). Halo-Lido is a topical formulation of halobetasol propionate, a corticosteroid, and lidocaine that is intended for the treatment of hemorrhoids. The Company is also seeking to develop and commercialize the NoveCite mesenchymal stem cells (NC-iMSCs) to treat acute respiratory conditions with a near term focus on ARDS.

Webull offers Citius Pharmaceuticals Inc stock information, including NASDAQ: CTXR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CTXR stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CTXR stock methods without spending real money on the virtual paper trading platform.